Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72 USD | -6.12% | +5.93% | +0.53% |
Apr. 18 | Intra-Cellular Therapies Prices $500 Million Stock Offering | MT |
Apr. 17 | Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.53% | 7.51B | |
-6.02% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+52.09% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-2.85% | 8.07B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Transcript : Intra-Cellular Therapies, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07